The Wacker Biotechnology Center is in Munich, where the company has been conducting fundamental research for over a century.

This could lead to the development of precision allergy treatments that are fast acting, needle free, and tailored to individual allergen sensitivities.

Replacing defective microglia can halt ALSP—a fatal neurodegenerative disease—in mice and humans, offering hope for broader brain therapies.

The acquisition of Avivia aligns with Ofichem’s broader merger and acquisition agenda and ongoing investment strategy.

A newly developed generative AI model is helping researchers explore protein dynamics with increased speed. The deep learning system, called BioEmu, predicts the full range of conformations a protein ...

The designed proteins block hemoglobin from binding ChuA, an outer membrane bacterial protein, helping to inhibit E. coli's growth.

Pharmaceutical manufacturers are under immense pressure to streamline their processes, reduce waste, and improve output.